Wed, Oct 23, 2024
Dr Lal Pathlabs dividend 2024: The counter closed at Rs 3252.50 today, a fall of 1.96 per cent from the previous close of Rs 3,317.45 on the BSE.
More >
Fri, Sep 15, 2023
Big boom possible in diagnostics sector in next 3-5 years... Target to maintain margin up to 27% in Q2 also: Ved Goyal, Group CFO, Dr Lal PathLabs
Fri, Jul 28, 2023
Dr Lal PathLabs Management in NewsParViews Q1 profit up 45% to ₹84 Cr margin Where did the support come from What were the key triggers for the results? Watch an exclusive interview with Ved P Goyal, Group CFO, DrLalPathLabs
Thu, May 11, 2023
Revenue from operations rose to Rs 491 crore for the fourth quarter as compared with Rs 485 crore in the year-ago period, Dr Lal PathLabs said in a regulatory filing.
Tue, Mar 28, 2023
How is the preparation going on against Corona? How much does the company benefit from increasing Covid testing? Watch Swati Khandelwal's exclusive interview with Ved P Goel, Group CFO, Dr Lal Path Labs.
Tue, Dec 13, 2022
Reports indicated that the facility will be initially extended to government hospitals and mohalla clinics
Wed, Nov 30, 2022
Stocks to buy: Brokerage firms have recommended five stocks that can yield up to 39 per cent.
Wed, Nov 09, 2022
Dr Lal Pathlabs share price: On NSE, at closing, the stock traded in red at Rs 2,414 which was down by 8.05 per cent.
Fri, Jul 08, 2022
Margins expected to remain up to 29% with increased testing. Focus is on capacity expansion in South India: Dr Arvind Lal, Executive Chairman, Dr Lal Path Labs. Watch an exclusive conversation with the top management of Dr Lal Path Labs.
Wed, May 18, 2022
Bullish Arguments: Over 12% jump in non-covid portfolio. Acquisition will reduce the cost of testing, and reach will also increase. Income growth is possible by starting many other tests. City Buying Opinion, Target ₹ 3460. Bearish Arguments: Worse than expected results, margins fall by more than 3%. Changes in B2C Lab Testing prices may affect profits. The reduction in covid testing will have an impact on the total volume. CLSA sell sentiment remains intact, target ₹ 2100.
Diagnostic companies Dr Lal Path Labs and Metropolis Healthcare shares were reeling under the pressure on Wednesday and declined even when the markets were trading in the green.
How were the results of Dr Lal Path Labs? Profit down 26.5% in Q4 to ₹61.3 Cr. What were the reasons for the decline in margins? What were the key triggers for the results? Watch an exclusive conversation with the management of Dr Lal Path Labs on the results.
Indian markets continue to gain for the third straight session on Wednesday amid positive global cues.
Tue, May 17, 2022
Q4 Results 2022: State-run IOC announced its March quarter results on Tuesday. Othet listed companies including Dr Lal Path Labs, Bajaj Electricals and IRB Infra were also among the companies which declared their January to March quarter earnings
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
